(Q33402671)

English

A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

multiple myeloma

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

object named as

John Rediske

9

0 references

Edward A. Stadtmauer

11

object named as

Edward A Stadtmauer

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

William Bensinger

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Richard T Maziarz

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sundar Jagannath

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Andrew Spencer

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Simon Durrant

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Pamela S Becker

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Brett Ewald

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sanela Bilic

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Johan Baeck

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

4 August 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

159

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

58-66

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09251.X

21 January 2018

Functional signatures identified in B-cell non-Hodgkin lymphoma profiles.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09251.X

21 January 2018

Molecular and biological characterization of a murine ligand for CD40

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09251.X

21 January 2018

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09251.X

21 January 2018

Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09251.X

21 January 2018

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09251.X

21 January 2018

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09251.X

21 January 2018

Cooperation of multiple signaling pathways in CD40-regulated gene expression in B lymphocytes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09251.X

21 January 2018

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09251.X

21 January 2018

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09251.X

21 January 2018

Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09251.X

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09251.X

21 January 2018

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09251.X

21 January 2018

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09251.X

21 January 2018

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09251.X

21 January 2018

CD40, but not CD154, expression on B cells is necessary for optimal primary B cell responses

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09251.X

21 January 2018

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09251.X

21 January 2018

The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09251.X

21 January 2018

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09251.X

21 January 2018

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09251.X

21 January 2018

Design and analysis of phase I clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09251.X

21 January 2018

Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09251.X

21 January 2018

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09251.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2012.09251.X

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33402671&oldid=1975572960"